Hydroxychloroquine

CHEMBL1535 Phase 4 已批准 Small molecule
Half-Life
40-50 days
Bioavailability
Protein Binding
Molecular Weight
335.9 g/mol
LogP
3.6
Phase
4

An antimalarial repurposed for autoimmune disease, hydroxychloroquine now treats rheumatoid arthritis, lupus, and Sjögren's syndrome more often than the parasitic infection it was designed for. It accumulates inside lysosomes and raises their internal pH, which interferes with antigen processing and dampens toll-like receptor signaling, reducing the output of inflammatory cytokines. A small molecule (C18H26ClN3O), it is remarkable for an extraordinarily long half-life of roughly 40 to 50 days, so it builds up slowly and clears just as slowly from the body. That prolonged retention, together with a tendency to deposit in the retina, is why periodic eye examinations accompany long-term use. Hydroxychloroquine is an approved medicine central to the management of several autoimmune conditions.

Originally developed as an antimalarial drug, this medication is widely used to treat autoimmune diseases including rheumatoid arthritis, lupus, and Sjögren's syndrome. It modulates the immune system by interfering with antigen processing and reducing the production of inflammatory cytokines. Regular eye examinations are recommended during long-term use due to a risk of retinal damage.

分子量

335.8720 g/mol

LogP

3.60

TPSA

48.40 Ų

Lipinski 五规则

符合

治疗领域

药物分类

作用机制

Accumulates in lysosomes raising pH; inhibits toll-like receptor signaling.

Pharmacokinetics (PK)

Half-Life 40-50 days

Pharmacodynamics (PD)

机制

Accumulates in lysosomes raising pH; inhibits toll-like receptor signaling.

二维结构

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12

InChI

InChI=1S/C18H26ClN3O/c1-3-22(11-12-23)10-4-5-14(2)21-17-8-9-20-18-13-15(19)6-7-16(17)18/h6-9,13-14,23H,3-5,10-12H2,1-2H3,(H,20,21)

Molecular Formula

C18H26ClN3O

HBD / HBA

2 / 4

可旋转键数

9

重原子数

23

Primary Target

No side effects recorded

Side effect data is not yet available for this drug.

常见问题

Originally developed as an antimalarial drug, this medication is widely used to treat autoimmune diseases including rheumatoid arthritis, lupus, and Sjögren's syndrome. It modulates the immune system by interfering with antigen processing and reducing the production of inflammatory cytokines. Regular eye examinations are recommended during long-term use due to a risk of retinal damage.

Accumulates in lysosomes raising pH; inhibits toll-like receptor signaling.

Key pharmacokinetic parameters for Hydroxychloroquine: Half-life: 40-50 days.

Yes, Hydroxychloroquine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

Related Drugs

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1535. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 3652. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

医疗免责声明

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.